Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

Fig. 2

Proportion of patients reporting improvements ≥ MCIDa in SF-36 at weeks 12 (A) and 24 (B). aMCID was defined as increase ≥5.0 for all SF-36 domains. bABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1000 mg). cNNTs are for UPA vs ABA. ABA abatacept, BP bodily pain, GH general health, IV intravenous, MCID minimal clinically important difference, MH mental health, PF physical functioning, RE role emotional, RP role physical, SF social functioning, SF-36 36-Item Short Form Health Survey, UPA upadacitinib, VT vitality. *P<0.05 for UPA vs ABA. P values represent statistical significance between treatment groups

Back to article page